SCHEMBL165537

SCHEMBL165537

CCCCCCCCCCCCC(C(=O)O)C(=O)C(O)CO

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.60
FFAR1 O14842 2/20 0.60
MAPT P10636 2/20 0.48
LCK P06239 1/20 0.48
PPARD Q03181 1/20 0.48
ZDHHC20 Q5W0Z9 1/20 0.48
ZDHHC2 Q9UIJ5 1/20 0.48
FFAR4 Q5NUL3 1/20 0.46
ACE2 Q9BYF1 1/20 0.46
LMNA P02545 2/20 0.45
CYP2D6 P10635 2/20 0.43
SPHK1 Q9NYA1 1/20 0.43
GMNN O75496 1/20 0.43
POLB P06746 1/20 0.43
THPO P40225 1/20 0.43
MTOR P42345 1/20 0.43
BLM P54132 1/20 0.43
KDM4E B2RXH2 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1237975 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL425589 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL168064 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL167865 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL17646227 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL167222 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL584656 1.00 GPR84 (0.60) GPR84FFAR1MAPTLCKPPARD
SCHEMBL5740376 0.98 GPR84 (0.57) GPR84FFAR1MAPTLCKPPARD
SCHEMBL2858482 0.96 GPR84 (0.56) GPR84FFAR1MAPTLCKPPARD
SCHEMBL6910867 0.95 GPR84 (0.55) GPR84FFAR1MAPTLCKPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 534 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021058158-A1 PRODUCT FOR DYEING KERATINOUS MATERIAL, CONTAINING AMINOSILICONE, A CHROMOPHORIC COMPOUND AND ETHOXYLATED FATTY ACID ESTER HENKEL AG & CO. KGAA (DE) 2021-04-01 WO claimed
EP-2988731-B1 COMPOSITION FOR USE IN REDUCING SCAB FORMATION AND PROMOTING HEALING BIOGLAN AB (SE) 2021-02-17 EP claimed
EP-3210474-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING POLYPEPTIDES AND RELATED METHODS OF DELIVERY CHIASMA INC (US) 2020-11-18 EP claimed
EP-3233035-B1 THICKENING DEVELOPER FOR OXIDATION PRODUCTS HENKEL AG & CO KGAA (DE) 2019-05-01 EP claimed
EP-3233035-A1 THICKENING DEVELOPER FOR OXIDATION DYES Henkel AG & Co. KGaA (DE) 2017-10-25 EP claimed
EP-2827829-B1 PEG-FREE ANTIPERSPIRANT OIL-IN-WATER EMULSIONS HAVING IMPROVED FEEL HENKEL AG & CO KGAA (DE) 2017-02-08 EP claimed
WO-2016096223-A1 THICKENING DEVELOPER FOR OXIDATION DYES HENKEL AG & CO. KGAA (DE) 2016-06-23 WO claimed
EP-2827829-A2 PEG-FREE ANTIPERSPIRANT OIL-IN-WATER EMULSIONS HAVING IMPROVED FEEL Henkel AG & Co. KGaA (DE) 2015-01-28 EP claimed
WO-2013092186-A2 PEG-FREE ANTIPERSPIRANT OIL-IN-WATER EMULSIONS HAVING IMPROVED FEEL HENKEL AG & CO. KGAA (DE) 2013-06-27 WO claimed
EP-1521573-B1 NON-POLYMERIC LIPOPHILIC PHARMACEUTICAL IMPLANT COMPOSITIONS FOR INTRAOCULAR USE ALCON INC (CH) 2008-01-02 EP claimed
EP-1436299-A4 METHOD FOR CRYSTALLIZATION OF 7-AMINOCEPHALOSPORANIC ACID CKD BIO CORP (KR) 2005-01-19 EP claimed
EP-1436299-A1 METHOD FOR CRYSTALLIZATION OF 7-AMINOCEPHALOSPORANIC ACID CKD BIO CORP. (KR) 2004-07-14 EP claimed
WO-2003031451-A1 METHOD FOR CRYSTALLIZATION OF 7-AMINOCEPHALOSPORANIC ACID CKD BIO CORP. (KR) 2003-04-17 WO claimed
EP-1250331-A1 FORMULATION FOR PROTECTION AGAINST OXIDATIVE STRESS CONTAINING BENZOFURANONE DERIVATIVES MERCK PATENT GmbH (DE) 2002-10-23 EP claimed
WO-2001055128-A1 FORMULATION FOR PROTECTION AGAINST OXIDATIVE STRESS CONTAINING BENZOFURANONE DERIVATIVES MERCK PATENT GMBH (DE) 2001-08-02 WO claimed
US-20230310391-A1 COMBINATION OF AN ANTIMUSCARINIC OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF CELLIX BIO PRIVATE LIMITED (IN) 2023-10-05 US disclosed
US-11730864-B2 Drug coated balloon catheters for nonvascular strictures UROTRONIC, INC. (US) 2023-08-22 US disclosed
EP-0775481-A1 Stable and free of hydrocarbons cosmetic or dermatologic oleogels and O/W emulsions Beiersdorf Aktiengesellschaft (DE) 1997-05-28 EP disclosed
WO-1996028131-A2 COSMETIC OR PHARMACEUTICAL MICROEMULSIONS BEIERSDORF AG (DE) 1996-09-19 WO disclosed
WO-1996028132-A2 COSMETIC OR DERMATOLOGICAL GELS BASED ON MICROEMULSIONS BEIERSDORF AG (DE) 1996-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310391-A1 COMBINATION OF AN ANTIMUSCARINIC OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF ACHE, CHRM2, ALOX5 GPR84 2361/4885FFAR1 1517/4885MAPT 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.